TD 1473

Drug Profile

TD 1473

Alternative Names: TD-1473

Latest Information Update: 12 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theravance Biopharma
  • Class Small molecules
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastrointestinal disorders; Ulcerative colitis

Most Recent Events

  • 27 Feb 2018 Theravance Biopharma plans a phase II trial in Crohn's disease (as induction therapy) in the second half of 2018 (Trial profile 700292956)
  • 27 Feb 2018 Theravance plans a phase IIb/II in Ulcerative colitis (as induction and maintenance therapy) in the second half of 2018 (Trial profile 700287689)
  • 07 Feb 2018 Janssen signs collaboration agreement with Theravance Biopharma for treatment of Inflammatory bowel disease including Crohn's disease and Ulcerative colitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top